Compare DAO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | STOK |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | China | United States |
| Employees | 3595 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2019 | 2019 |
| Metric | DAO | STOK |
|---|---|---|
| Price | $14.60 | $28.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $39.20 |
| AVG Volume (30 Days) | 72.4K | ★ 678.1K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | $77.49 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $8.38 | $20.32 |
| 52 Week High | $18.94 | $40.22 |
| Indicator | DAO | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 38.77 |
| Support Level | $9.26 | $28.02 |
| Resistance Level | $18.79 | $33.61 |
| Average True Range (ATR) | 0.89 | 1.21 |
| MACD | -0.14 | -0.25 |
| Stochastic Oscillator | 33.91 | 17.50 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.